RELMADA THERAPEUTICS, INC. Increase (Decrease) in Other Receivables
RELMADA THERAPEUTICS, INC. (RLMD) reported Increase (Decrease) in Other Receivables of $10.91 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. increase (decrease) in other receivables for the quarter ending 2023-12-31 was $0.00.
- RELMADA THERAPEUTICS, INC. increase (decrease) in other receivables for the quarter ending 2023-09-30 was $0.00.
- RELMADA THERAPEUTICS, INC. increase (decrease) in other receivables for the quarter ending 2023-06-30 was $0.00.
- RELMADA THERAPEUTICS, INC. increase (decrease) in other receivables for the quarter ending 2023-03-31 was -$512.43K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in other receivables for fiscal 2023 was -$512.43K, a 200.00% decline from fiscal 2022.
- RELMADA THERAPEUTICS, INC. increase (decrease) in other receivables for fiscal 2022 was $512.43K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in other receivables for fiscal 2019 was $169.36K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in other receivables for fiscal 2018 was -$224.98K, a 34448.09% decline from fiscal 2017.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 6 month | Increase (Decrease) in Other Receivables 9 month | Increase (Decrease) in Other Receivables 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.91K 10-Q · filed 2026-08-06 | |||
| 2025-09-30 | $212.21K 10-Q · filed 2025-11-13 | |||
| 2024-09-30 | $283.80K 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 derived: sum of 2 quarters · filed 2025-03-27 | $0.00 derived: sum of 3 quarters · filed 2025-03-27 | -$512.43K 10-K · filed 2025-03-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | -$512.43K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$512.43K 10-Q · filed 2023-08-08 | ||
| 2023-03-31 | -$512.43K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $512.43K 10-K · filed 2024-03-19 | |||
| 2022-06-30 | $256.19K 10-Q · filed 2023-08-08 | |||
| 2020-03-31 | $7.53K 10-Q · filed 2021-05-12 | $7.53K derived: sum of 2 quarters · filed 2021-05-12 | -$169.45K derived: sum of 3 quarters · filed 2021-05-12 | $7.53K derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $0.00 derived: 10-K 6 month − 10-Q 3 month · filed 2021-03-24 | -$176.98K 10-K · filed 2021-03-24 | $0.00 derived: sum of 3 quarters · filed 2021-03-24 | $0.00 derived: sum of 4 quarters · filed 2021-03-24 |
| 2019-09-30 | -$176.98K 10-Q · filed 2019-11-13 | $0.00 derived: sum of 2 quarters · filed 2021-03-24 | $0.00 derived: sum of 3 quarters · filed 2021-03-24 | $0.00 derived: sum of 4 quarters · filed 2021-03-24 |
| 2019-06-30 | $176.98K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $176.98K 10-Q · filed 2020-08-12 | $176.98K derived: sum of 3 quarters · filed 2021-03-24 | $169.36K 10-K · filed 2021-03-24 |
| 2019-03-31 | $0.00 derived: 10-Q 9 month − 10-KT 6 month · filed 2019-05-15 | $0.00 derived: sum of 2 quarters · filed 2020-03-26 | -$7.62K 10-Q · filed 2019-05-15 | $0.00 derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-12-31 | $0.00 derived: 10-KT 6 month − 10-Q 3 month · filed 2020-03-26 | -$7.62K 10-KT · filed 2020-03-26 | $0.00 derived: sum of 3 quarters · filed 2020-03-26 | $0.00 derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-09-30 | -$7.62K 10-Q · filed 2019-11-13 | $0.00 derived: sum of 2 quarters · filed 2020-03-26 | $0.00 derived: sum of 3 quarters · filed 2020-03-26 | -$150.62K derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-06-30 | $7.62K derived: 10-KT 12 month − 10-Q 9 month · filed 2020-03-26 | $7.62K derived: sum of 2 quarters · filed 2020-03-26 | -$143.00K derived: sum of 3 quarters · filed 2020-03-26 | -$224.98K 10-KT · filed 2020-03-26 |
| 2018-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-15 | -$150.62K derived: sum of 2 quarters · filed 2019-05-15 | -$232.60K 10-Q · filed 2019-05-15 | |
| 2017-12-31 | -$150.62K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-13 | -$232.60K 10-Q · filed 2019-02-13 | ||
| 2017-09-30 | -$81.98K 10-Q · filed 2018-11-13 | |||
| 2017-06-30 | $655.00 10-K · filed 2018-09-28 | |||
| 2016-09-30 | $2.35K 10-Q · filed 2017-11-14 | |||
| 2016-06-30 | $231.94K 10-K · filed 2017-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |